Biomark Diagnostics Inc. (CSE:BUX)

Revenue by Product

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2019
Early-stage Cancer Diagnostic Technology Platform	154.22K
Early-stage Cancer Diagnostic Technology Platform Growth	-5.52%

Revenue by Geography

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2019
Canada	154.22K
Canada Growth	-5.52%